https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

IBI303, Humira Biosimilar, Shows Comparable Efficacy and Cost Benefit to Reference Product

IBI303, Humira Biosimilar, Shows Comparable Efficacy and Cost Benefit to Reference Product

There were also no observed differences in retention rates or safety among patients with ankylosing spondylitis.

administrator

Related Articles